title: Chronic inflammatory IFN-γ signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosis.
abstract: Chronic liver inflammation is a critical component of hepatocarcinogenesis. Indeed, inflammatory mediators are believed to promote liver cancer by upholding compensatory proliferation of hepatocytes in response to tissue damage. However, inflammation can also mediate the depletion of malignant cells, but the difference between tumor-suppressive and tumor-promoting inflammation is not defined at the molecular level. Here, we analyzed the role of the major inflammatory mediator IFN-γ in chemical hepatocarcinogenesis of transgenic mice that overexpress IFN-γ in the liver; these mice manifest severe chronic inflammatory liver damage and lasting compensatory regeneration. We found that chronic exposure to IFN-γ suppressed chemical hepatocarcinogenesis, despite overt liver injury. Indeed, IFN-γ-transgenic mice had significantly fewer and significantly less advanced malignant lesions than nontransgenic mice. This tumor-suppressive effect of IFN-γ seemed to be mediated in part by its known immune activating function, indicated by infiltration of IFN-γ-transgenic livers with CD8 T cells, natural killer T cells, and natural killer cells. However, IFN-γ seemed to prevent carcinogenesis also by activating the cell-intrinsic p53 tumor suppressor pathway. Indeed, exposure to IFN-γ in vivo or in vitro was associated with accumulation of p53 in hepatocytes and the sensitization of hepatocytes to apoptosis induced by genotoxic stress. The IFN-γ-induced increase in apoptosis of hepatocytes seemed to be p53 dependent. Thus, chronic inflammation dominated by IFN-γ may prevent hepatocarcinogenesis, despite continued inflammatory liver injury and regeneration. Therefore, the carcinogenic potential of inflammation seems to be determined by type and composition of its mediators and manipulating the type of chronic inflammation may serve the prevention of cancer.
authors.affiliation: Department of Medicine I, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Lüth
authors.forename: Jörg
authors.initials: J
authors.lastname: Schrader
authors.forename: Stefan
authors.initials: S
authors.lastname: Zander
authors.forename: Antonella
authors.initials: A
authors.lastname: Carambia
authors.forename: Juliane
authors.initials: J
authors.lastname: Buchkremer
authors.forename: Samuel
authors.initials: S
authors.lastname: Huber
authors.forename: Kurt
authors.initials: K
authors.lastname: Reifenberg
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Yamamura
authors.forename: Peter
authors.initials: P
authors.lastname: Schirmacher
authors.forename: Ansgar W
authors.initials: AW
authors.lastname: Lohse
authors.forename: Johannes
authors.initials: J
authors.lastname: Herkel
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D002478:Cells, Cultured; D022781:Hepatocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D018836:Inflammation Mediators / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology* / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000276:immunology* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D018836:Inflammation Mediators; D016159:Tumor Suppressor Protein p53; D007371:Interferon-gamma